Stock listing
BMV:ORYN Oryzon Genomics SA Acciones
Mexican listing (BMV) of Oryzon Genomics SA · home listing BME:ORY
Follow Oryzon Genomics SA into a list and get an email when it puts out news.
Home listing price · BME:ORY
€2.41 EUR +0.09 (+3.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, BME:ORY
- Day range
- €2.39 – €2.49 EURNov 20, 2026
- Volume
- 376,082 sharesNov 20, 2026
- Market cap
- €197.2M EURAt the close on Nov 20, 2026 · price × 81.96M shares outstanding
- 52-week range
- €2.23 – €3.56 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €505,710 EURMedian day 122,871 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| BME:ORY · Home | €2.406 EUR | +0.09 (+3.9%) | 376,082 | €2.408 | €2.49 | €2.386 | €2.316 | Close on Nov 20, 2026 |
| LSE:0RDB | €2.42 EUR | -0.096 (-3.8%) | 2,088 | €2.458 | €2.458 | €2.42 | €2.516 | Close on Nov 20, 2026 |
| Frankfurt:ORN | €2.376 EUR | -0.004 (-0.2%) | — | €2.376 | €2.376 | €2.376 | €2.38 | Close on Nov 20, 2026 |
| Stuttgart:ORN | €2.372 EUR | -0.054 (-2.2%) | — | €2.41 | €2.464 | €2.372 | €2.426 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · BME:ORY · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €2.406 | +0.09 | +3.9% | €2.408 | €2.49 | €2.386 | 376,082 | |
| €2.316 | 0.00 | 0.0% | €2.312 | €2.34 | €2.306 | 99,949 | |
| €2.316 | -0.02 | -0.9% | €2.342 | €2.362 | €2.292 | 120,627 | |
| €2.336 | -0.01 | -0.4% | €2.30 | €2.48 | €2.23 | 735,313 | |
| €2.346 | -0.23 | -8.9% | €2.598 | €2.598 | €2.32 | 1,246,862 | |
| €2.576 | +0.102 | +4.1% | €2.578 | €2.59 | €2.514 | 355,206 | |
| €2.474 | +0.048 | +2.0% | €2.422 | €2.494 | €2.402 | 194,878 | |
| €2.426 | +0.048 | +2.0% | €2.39 | €2.47 | €2.39 | 321,112 | |
| €2.378 | +0.046 | +2.0% | €2.362 | €2.39 | €2.286 | 433,133 | |
| €2.332 | -0.022 | -0.9% | €2.374 | €2.40 | €2.324 | 260,525 | |
| €2.354 | -0.038 | -1.6% | €2.438 | €2.474 | €2.354 | 287,153 | |
| €2.392 | 0.00 | 0.0% | €2.388 | €2.42 | €2.382 | 152,469 | |
| €2.392 | +0.052 | +2.2% | €2.33 | €2.514 | €2.31 | 528,206 | |
| €2.34 | -0.088 | -3.6% | €2.388 | €2.42 | €2.302 | 564,066 | |
| €2.428 | -0.07 | -2.8% | €2.49 | €2.506 | €2.404 | 178,481 | |
| €2.498 | +0.004 | +0.2% | €2.484 | €2.518 | €2.484 | 82,005 | |
| €2.494 | -0.016 | -0.6% | €2.512 | €2.534 | €2.48 | 121,183 | |
| €2.51 | +0.01 | +0.4% | €2.53 | €2.532 | €2.49 | 99,097 | |
| €2.50 | 0.00 | 0.0% | €2.504 | €2.522 | €2.494 | 98,723 | |
| €2.50 | -0.03 | -1.2% | €2.54 | €2.556 | €2.486 | 123,421 | |
| €2.53 | -0.072 | -2.8% | €2.592 | €2.596 | €2.53 | 113,036 | |
| €2.602 | +0.022 | +0.9% | €2.55 | €2.61 | €2.55 | 90,954 | |
| €2.58 | +0.056 | +2.2% | €2.512 | €2.594 | €2.504 | 151,201 | |
| €2.524 | -0.024 | -0.9% | €2.554 | €2.558 | €2.512 | 106,442 | |
| €2.548 | -0.006 | -0.2% | €2.524 | €2.58 | €2.522 | 107,645 | |
| €2.554 | -0.018 | -0.7% | €2.58 | €2.58 | €2.492 | 266,940 | |
| €2.572 | +0.04 | +1.6% | €2.546 | €2.61 | €2.52 | 307,467 | |
| €2.532 | -0.146 | -5.5% | €2.646 | €2.664 | €2.48 | 619,616 | |
| €2.678 | +0.028 | +1.1% | €2.674 | €2.69 | €2.656 | 73,218 | |
| €2.65 | +0.02 | +0.8% | €2.64 | €2.694 | €2.60 | 188,889 | |
| €2.63 | -0.07 | -2.6% | €2.698 | €2.698 | €2.60 | 243,876 | |
| €2.70 | -0.018 | -0.7% | €2.708 | €2.718 | €2.68 | 59,792 | |
| €2.718 | +0.018 | +0.7% | €2.69 | €2.738 | €2.672 | 273,107 | |
| €2.70 | -0.032 | -1.2% | €2.75 | €2.756 | €2.68 | 220,508 | |
| €2.732 | -0.022 | -0.8% | €2.75 | €2.75 | €2.712 | 85,250 | |
| €2.754 | -0.024 | -0.9% | €2.758 | €2.774 | €2.71 | 81,838 | |
| €2.778 | +0.068 | +2.5% | €2.71 | €2.78 | €2.71 | 190,927 | |
| €2.71 | -0.04 | -1.5% | €2.75 | €2.756 | €2.71 | 164,753 | |
| €2.75 | +0.018 | +0.7% | €2.76 | €2.808 | €2.73 | 216,114 | |
| €2.732 | +0.002 | +0.1% | €2.72 | €2.76 | €2.72 | 91,297 | |
| €2.73 | -0.002 | -0.1% | €2.76 | €2.76 | €2.69 | 201,664 | |
| €2.732 | -0.064 | -2.3% | €2.79 | €2.792 | €2.73 | 173,197 | |
| €2.796 | +0.02 | +0.7% | €2.78 | €2.818 | €2.774 | 55,682 | |
| €2.776 | -0.012 | -0.4% | €2.772 | €2.788 | €2.752 | 38,387 | |
| €2.788 | -0.024 | -0.9% | €2.828 | €2.828 | €2.77 | 55,352 | |
| €2.812 | +0.01 | +0.4% | €2.814 | €2.83 | €2.80 | 60,078 | |
| €2.802 | +0.008 | +0.3% | €2.82 | €2.82 | €2.778 | 34,500 | |
| €2.794 | +0.02 | +0.7% | €2.798 | €2.814 | €2.76 | 89,990 | |
| €2.774 | -0.014 | -0.5% | €2.82 | €2.82 | €2.764 | 63,495 | |
| €2.788 | -0.008 | -0.3% | €2.79 | €2.808 | €2.78 | 96,764 | |
| €2.796 | +0.022 | +0.8% | €2.77 | €2.816 | €2.77 | 71,303 | |
| €2.774 | -0.036 | -1.3% | €2.83 | €2.83 | €2.77 | 88,446 | |
| €2.81 | +0.022 | +0.8% | €2.82 | €2.838 | €2.80 | 200,980 | |
| €2.788 | -0.006 | -0.2% | €2.80 | €2.804 | €2.764 | 80,395 | |
| €2.794 | -0.018 | -0.6% | €2.82 | €2.82 | €2.79 | 57,828 | |
| €2.812 | 0.00 | 0.0% | €2.78 | €2.848 | €2.78 | 44,253 | |
| €2.812 | +0.02 | +0.7% | €2.814 | €2.84 | €2.762 | 109,055 | |
| €2.792 | -0.006 | -0.2% | €2.798 | €2.808 | €2.766 | 110,204 | |
| €2.798 | -0.012 | -0.4% | €2.87 | €2.87 | €2.794 | 171,317 | |
| €2.81 | -0.01 | -0.4% | €2.83 | €2.878 | €2.75 | 367,327 | |
| €2.82 | -0.02 | -0.7% | €2.864 | €2.864 | €2.818 | 130,044 | |
| €2.84 | -0.016 | -0.6% | €2.864 | €2.868 | €2.84 | 72,811 | |
| €2.856 | +0.02 | +0.7% | €2.82 | €2.874 | €2.82 | 74,075 | |
| €2.836 | -0.018 | -0.6% | €2.878 | €2.878 | €2.812 | 122,320 | |
| €2.854 | +0.066 | +2.4% | €2.81 | €2.88 | €2.788 | 201,092 | |
| €2.788 | -0.038 | -1.3% | €2.88 | €2.88 | €2.784 | 275,559 |
- Ticker
- BMV:ORY/N
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BMV
- Currency
- MXN
What changed lately
Latest news release · Nov 13, 2026
Internal Regulations for Conduct in the Securities Markets
Latest deck · March 2026
Investor Presentation (March 2026)
Investor deck · 43 slides
Latest news
Internal Regulations for Conduct in the Securities Markets
Nov 13, 2026
Closed €2.34 (-0.4%) on Nov 16, 2026
Oryzon Genomics S A to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
Nov 4, 2026
Closed €2.39 (0.0%) on Nov 4, 2026
Oryzon Genomics S A announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
Nov 3, 2026
Closed €2.39 (+2.2%) on Nov 3, 2026
Oryzon Genomics S A to participate in upcoming events in November
Oct 28, 2026
Closed €2.49 (-0.6%) on Oct 28, 2026
Oryzon Genomics S A further strengthens vafidemstat’s patent portfolio with new decisions to grant
Oct 15, 2026
Closed €2.55 (-0.7%) on Oct 15, 2026
ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study of vafidemstat for the treatment of Phelan-McDermid Syndrome
Sep 29, 2026
Closed €2.71 (-1.5%) on Sep 29, 2026
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
Sep 28, 2026
Closed €2.75 (+0.7%) on Sep 28, 2026
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
Aug 31, 2026
Closed €2.80 (-0.4%) on Aug 31, 2026
Oryzon Genomics S A reports financial results and corporate update for half year ended June 30th, 2026
Jul 27, 2026
Closed €2.95 (-1.3%) on Jul 28, 2026
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)
Jul 8, 2026
Closed €2.92 (-1.5%) on Jul 8, 2026
Financings
Shares (capital increase)
Jul 27, 2026 · US$13.65M
Closed: €12M raised
Use of proceeds: To support the pipeline through the clinical catalysts expected this year and beyond
Strategic investment of newly issued Oryzon shares
Jul 27, 2026 · US$28.44M
Update: €25M
Buyers: Social Impact Fund (committed, as an anchor investor, to subscribe for newly issued shares for an aggregate investment of €25 million)
Use of proceeds: To support Oryzon's mental health programs
Private placement of new ordinary shares
Jul 1, 2026 · US$13.7M
Closed: €12M raised · €2.7 a share · Singular Bank +1
Dealers: Singular Bank, All-Invest
Use of proceeds: Strengthen balance sheet, advance iadademstat in AML, progress other hematology and psychiatry programs, cover G&A and financial obligations
Strategic investment of newly created Oryzon shares
Jul 1, 2026 · US$28.53M
Announced: €25M
Buyers: Social Impact Fund (committed to subscribe for newly created shares for a total investment amount of €25 million)
Use of proceeds: R&D in central nervous system, oncology and hematology; at least 40% to mental health programs, notably borderline personality disorder
Shares (capital increase through cash contributions)
Dec 15, 2025 · US$146.9M
Announced: up to €125M
Convertible bonds
Jul 30, 2025
Cancelled: convertible
Buyers: Nice & Green, S.A.; Nice & Green
Private placement of new shares
Apr 24, 2025 · US$34.12M
Closed: €30M raised · €2.35 a share · Maxim +2
Dealers: Maxim (co-lead), All-Invest (co-lead), Singular Bank (co-lead)
Buyers: US-based institutional investor (€15 million order)
Use of proceeds: Clinical development of vafidemstat, oncology and hematology programs, CMC and Phase IIb-III preparation, balance sheet, general expenses, Nasdaq listing readiness
Decks
Investor Presentation (March 2026)
Investor deck · 43 slides · March 2026
ECNP 2024
Conference · 21 slides · Sep 23, 2024
Investor Presentation (July 2024)
Investor deck · 55 slides · July 2024
Technical Presentation (January 2024)
Technical · 24 slides · Jan 25, 2024
Oryzon Genomics SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 32 in the last 12 months · 174 in all · newest Nov 13, 2026 · oldest 2015
- Decks
- 18 decks · latest March 2026
Where Oryzon Genomics SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| BME:ORY · Home listing | Madrid | Spain | EUR |
| gettex:ORN | gettex | Germany | EUR |
| LS Exchange:A2ACV2 | LS Exchange | Germany | EUR |
| LSE:0RDB | LSE | United Kingdom | EUR |
| OTC:ORYZF | OTC | United States | USD |
| Lang & Schwarz:A2ACV2 | Lang & Schwarz | Germany | EUR |
| Aquis:ORYE | Aquis | United Kingdom | EUR |
| BMV:ORYN · This page | BMV | Mexico | MXN |
| Tradegate:ORN | Tradegate | Germany | EUR |
| Aquis:ORYE | Aquis | United Kingdom | EUR |
| BIVA:ORYN | BIVA | Mexico | MXN |
| Dusseldorf:ORN | Dusseldorf | Germany | EUR |
| Frankfurt:ORN | Frankfurt | Germany | EUR |
| Hamburg:ORN | Hamburg | Germany | EUR |
| Munich:ORN | Munich | Germany | EUR |
| Stuttgart:ORN | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Oryzon Genomics SA.